Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APX005M in Immunotherapy-Naive Metastatic Melanoma
2018-003864-30Phase 2Terminated
- Sponsor
- Apexigen, Inc.
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of sotigalimab in melanoma, sponsored by Apexigen, Inc. Primary endpoint: Overall response rate by RECIST 1.1. Started Jan 2019; status: terminated.
02
Drugs
sotigalimab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2018-003864-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003864-30.